- Home
- IVA vs ARCT Comparison
IVA vs ARCT Comparison
Compare IVA & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- ARCT
- Stock Information
- Founded
- IVA 2011
- ARCT 2013
- Country
- IVA France
- ARCT United States
- Employees
- IVA N/A
- ARCT N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- ARCT Health Care
- Exchange
- IVA Nasdaq
- ARCT Nasdaq
- Market Cap
- IVA 359.6M
- ARCT 298.3M
- IPO Year
- IVA 2020
- ARCT N/A
- Fundamental
- Price
- IVA $3.07
- ARCT $13.95
- Analyst Decision
- IVA Strong Buy
- ARCT Strong Buy
- Analyst Count
- IVA 4
- ARCT 8
- Target Price
- IVA $10.50
- ARCT $52.33
- AVG Volume (30 Days)
- IVA 27.3K
- ARCT 473.8K
- Earning Date
- IVA 03-26-2025
- ARCT 08-04-2025
- Dividend Yield
- IVA N/A
- ARCT N/A
- EPS Growth
- IVA N/A
- ARCT N/A
- EPS
- IVA N/A
- ARCT N/A
- Revenue
- IVA $14,591,573.00
- ARCT $143,680,000.00
- Revenue This Year
- IVA $15.38
- ARCT N/A
- Revenue Next Year
- IVA $24.22
- ARCT $34.79
- P/E Ratio
- IVA N/A
- ARCT N/A
- Revenue Growth
- IVA N/A
- ARCT 15.38
- 52 Week Low
- IVA $1.53
- ARCT $8.04
- 52 Week High
- IVA $4.05
- ARCT $27.54
- Technical
- Relative Strength Index (RSI)
- IVA 39.40
- ARCT 62.93
- Support Level
- IVA $3.25
- ARCT $12.03
- Resistance Level
- IVA $3.47
- ARCT $13.42
- Average True Range (ATR)
- IVA 0.23
- ARCT 0.81
- MACD
- IVA -0.04
- ARCT 0.09
- Stochastic Oscillator
- IVA 8.51
- ARCT 97.25
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.